Risk and safety of probiotics

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S129-S134

  Doron, Shira ^a   Snydman, David R ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

bacteremia; Lactobacillus; probiotics; Saccharomyces; safety

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; DISEASE SEVERITY; DRUG SAFETY; EVIDENCE BASED PRACTICE CENTER; GASTROINTESTINAL SYMPTOM; GENE TRANSFER; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; INCIDENCE; INTERVENTION STUDY; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; RISK ASSESSMENT; SCIENTIST; SYSTEMIC DISEASE; CLINICAL TRIAL (TOPIC); FUNGEMIA; GASTROINTESTINAL TRACT; HORIZONTAL GENE TRANSFER; LACTOBACILLUS; PATHOGENICITY; PHYSIOLOGY; RISK; SACCHAROMYCES; SEPSIS; STANDARDS; UNITED STATES;

CLINICAL TRIALS AS TOPIC; FUNGEMIA; GASTROINTESTINAL TRACT; GENE TRANSFER, HORIZONTAL; HUMANS; LACTOBACILLUS; PROBIOTICS; RISK; SACCHAROMYCES; SEPSIS; UNITED STATES;

EID: 84928881118     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ085     Document Type: Article

References (92)

1. BernardoW, Aires FT, Carneiro RM, et al. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: a systematic review and meta-analysis. J Pediatr 2013; 89: 18-24.
2. Khalesi S, Sun J, Buys N, et al. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014; 64: 897-903.
3. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
4. Wallace TC, MacKay D. The safety of probiotics: considerations following the 2011U.S. Agency for Health Research and Quality report. J Nutr 2011; 141: 1923-4.
5. Huang YF, Liu PY, Chen YY, et al. Three-combination probiotics therapy in children with salmonella and rotavirus gastroenteritis. J Clin Gastroenterol 2014; 48: 37-42.
6. Olivares M, Castillejo G, Varea V, Sanz Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br J Nutr 2014; 112: 30-40.
7. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001; 138: 361-5.
8. Kumar S, Singhi S, Chakrabarti A, et al. Probiotic use and prevalence of candidemia and candiduria in a PICU. Pediatr Crit Care Med 2013; 14: e409-15.
9. Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Australia 2007; 186: 454-7.
10. Maziade PJ, Andriessen JA, Pereira P, et al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013; 29: 1341-7.
11. Gao HW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula or Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105: 1636-41.
12. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74: 123-7.
13. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation: a randomized, double-blind trial. Am J Transplant 2005; 5: 125-30.
14. Saint-Marc T, Rossello-Prats L, Touraine JL. Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS. Ann Med Interne (Paris) 1991; 142: 64-5.
15. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99: 179-85.
16. Isolauri E, Arvola T, S?tas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30: 1604-10.
17. Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122: 8-12.
18. Weizman Z, Alsheikh A. Safety and Tolerance of a Probiotic Formula in Early Infancy Comparing Two Probiotic Agents: A Pilot Study. J Am Coll Nutr 2006; 25: 415-9.
19. Kalliom?ki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076-9.
20. Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122: 8-12.
21. Boyle RJ, Mah LJ, Chen A, Kivivuori S, Robins-Browne RM, Tang ML. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin Exp Allergy 2008; 38: 1882-90.
22. Rouge C, Piloquet H, Butel MJ, et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2009; 89: 1828-35.
23. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735-42.
24. Mohan R, Koebnick C, Schildt J, et al. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 2008; 64: 418-22.
25. Mohan R, Koebnick C, Schildt J, et al. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol 2006; 44: 4025-31.
26. Pellino G, Sciaudone G, Candilio G, et al. Early postoperative administration of probiotics versus placebo in elderly patients undergoing elective colorectal surgery: a double-blind randomized controlled trial. BMC Surg 2013; 13: S57.
27. Ahmed J, Reddy BS, Molbak L, et al. Impact of probiotics on colonic microflora in patients with colitis: a prospective double blind randomised crossover study. Int J Surg 2013; 11: 1131-6.
28. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 1: 833-9.
29. Bassetti S, Frei R, ZimmerliW. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 71-2.
30. Cesaro S, Chinello P, Rossi L, et al. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000; 8: 504-5.
31. Cherifi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clinica Belgica 2004; 59: 223-4.
32. Force G, Aznar C, Marguet F, et al. Saccharomyces fungemia in AIDS patients after treatment for chronic diarrhea. In: The Fifth European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen: September 1995.
33. Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 1998; 27: 222-3.
34. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19: 16-20.
35. Henry S, D'Hondt L, Andre M, et al. Saccharomyces cerevisiae fungemia in a head and neck cancer patient: a case report and review of the literature. Acta Clinica Belgica 2004; 59: 220-2.
36. Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28: 797-801.
37. Lolis N, Veldekis D, Moraitou H, et al. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin. Crit Care 2008; 12: 414.
38. Lungarotti MS, Mezzetti D, Radicioni M. Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida. Arch Dis Child Fetal Neonatal Ed 2003; 88: F446.
39. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625-34.
40. Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999; 28: 930.
41. Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000; 19: 468-70.
42. Piarroux R, Millon L, Bardonnet K, et al. Are live saccharomyces yeasts harmful to patients? Lancet 1999; 353: 1851-2.
43. Piechno S, Seguin P, Gangneux JP. [Saccharomyces boulardii fungal sepsis: beware of the yeast]. Can J Anaesth 2007; 54: 245-6.
44. PletinexM, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year old girl with protracted diarrhoea. J Pediatr Gastroenterol Nutr 1995; 21: 113-5.
45. Rijnders BJ, Van Wijngaerden E, Verwaest C, et al. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a nonimmunocompromised host. Intensive Care Med 2000; 26: 825.
46. Riquelme AJ, Calvo MA, Guzman AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36: 41-3.
47. Trautmann M, Synowzik I, Nadji-Ohl M, et al. Fungemia due to Saccharomyces cerevisiae var. boulardii. Chemother J 2008; 17: 57-61.
48. Viggiano M, Badetti C, Bernini V, et al. Saccharomyces boulardii fungemia in a patient with severe burns. Annales Francaises d'Anesthesie et de Reanimation 1995; 14: 356-8.
49. Zunic P, Lacotte J, Pegoix M, et al. Saccharomyces boulardii fungemia. Apropos of a case. Therapie 1991; 46: 498-9.
50. Santino I, Alari A, Bono S, et al. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol 2014; 27: 143-6.
51. Barton LL, Rider ED, Coen RW. Bacteremic infection with Pediococcus: vancomycin resistant opportunist. Pediatrics 2001; 107: 775-6.
52. De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005; 24: 278-80.
53. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS 2006; 17: 280-2.
54. Richard V, Van der Auwera P, Snoeck R, et al. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988; 7: 783-5.
55. Tommasi C, Equitani F, Masala M, et al. Diagnostic difficulties of Lactobacillus casei bacteraemia in immunocompetent patients: a case report. J Med Case Reports 2008; 2: 315.
56. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 2013; 47: 437-9.
57. Burkhardt O, Kohnlein T, Pletz M, et al. Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 2005; 37: 69-72.
58. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004; 38: 457-8.
59. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115: 178-81.
60. Lestin F, Pertschy A, Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr 2003; 128: 2531-3.
61. Oggioni MR, Pozzi G, Valensin PE, et al. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998; 36: 325-6.
62. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr 2010; 156: 679-81.
63. Zein EF, Karaa S, Chemaly A, et al. Lactobacillus rhamnosus septicemia in a diabetic patient associated with probiotic use: a case report. Ann Biol Clin (Paris) 2008; 66: 195-8.
64. Mackay AD, Taylor MB, Kibbler CC, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5: 290-2.
65. Presterl E, Kneifel W, Mayer HK, et al. Endocarditis by Lactobacillus rhamnosus due to yogurt ingestion? Scand J Infect Dis 2001; 33: 710-4.
66. Conen A, Zimmerer S, Frei R, et al. A pain in the neck: probiotics for ulcerative colitis. Ann Intern Med 2009; 151: 895-7.
67. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28: 1159-60.
68. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35: 1155-60.
69. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38: 62-9.
70. Ouwehand AC, Saxelin M, Salminen S. Phenotypic differences between commercial Lactobacillus rhamnosus GG and L. rhamnosus strains recovered from blood. Clin Infect Dis 2004; 39: 1858-60.
71. Sullivan A, Nord CE. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 2006; 38: 327-31.
72. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9.
73. Olah A, Belagyi T, Issekutz A, et al. Early enternal nutrition with specific Lactobacillus and fibre reduces sepsis in severe acute pancreatitis. Br J Surg 2002; 89: 1103-7.
74. Olah A, Belagyi T, Poto L, et al. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 2007; 54: 594-8.
75. Jain PK, McNaught CE, Anderson AD, et al. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin Nutr 2004; 23: 467-75.
76. Honeycutt TC, El KM, Wardrop RM III. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 2007; 8: 452-8.
77. Ku W. Probiotics provoked D-lactic acidosis in short bowel syndrome: case report and literature review. HK J Paediatr 2006; 11: 246-54.
78. Munakata S, Arakawa C, Kohira R, et al. A case of D-lactic acid encephalopathy associated with use of probiotics. Brain Dev 2010; 32: 691-4.
79. Oh MS, Phelps KR, Traube M, et al. D-lactic acidosis in a man with the short-bowel syndrome. N Engl J Med 1979; 301: 249-52.
80. Vaarala O. Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy 2003; 33: 1634-40.
81. Veckman V, Miettinen M, Pirhonen J, et al. Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. J Leukoc Biol 2004; 75: 764-71.
82. Braat H, de Jong EC, van den Brande JM, et al. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J Mol Med 2004; 82: 197-205.
83. Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun 2004; 72: 3299-309.
84. Lin CF, Fung ZF, Wu CL, et al. Molecular characterization of a plasmidborne (pTC82) chloramphenicol resistance determinant (cat-TC) from Lactobacillus reuteri G4. Plasmid 1996; 36: 116-24.
85. Gevers D, Danielsen M, Huys G, et al. Molecular characterization of tet (M) genes in Lactobacillus isolates from different types of fermented dry sausage. Appl Environ Microbiol 2003; 69: 1270-5.
86. Tannock GW, Luchansky JB, Miller L, et al. Molecular characterization of a plasmid-borne (pGT633) erythromycin resistance determinant (ermGT) from Lactobacillus reuteri 100-63. Plasmid 1994; 31: 60-71.
87. Dessart SR, Steenson LR. High frequency intergeneric and intrageneric transfer conjugal transfer of drug resistance plasmids in Leuconostoc mesenteroides ssp. cremoris. J Dairy Sci 1991; 74: 2912-9.
88. Morelli L, Sarra PG, Bottazzi V. In vivo transfer of pAM beta 1 from Lactobacillus reuteri to Enterococcus faecalis. J Appl Bacteriol 1988; 65: 371-5.
89. Klein G, Hallmann C, Casas IA, et al. Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridization methods. J Appl Microbiol 2000; 89: 815-24.
90. Tynkkynen S, Singh KV, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998; 41: 195-204.
91. Johnston BC, Ma SSY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 878-88.
92. Goldenberg JZ, Ma SYY, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5.